{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T08:27:37Z","timestamp":1725870457444},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T00:00:00Z","timestamp":1524614400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00108-018-0429-y","type":"journal-article","created":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T12:32:22Z","timestamp":1524659542000},"page":"528-535","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Chronische Hepatitis\u00a0C"],"prefix":"10.1007","volume":"59","author":[{"given":"S.","family":"Zeuzem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,25]]},"reference":[{"key":"429_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/hep.28995","volume":"66","author":"WF Balistreri","year":"2017","unstructured":"Balistreri WF, Murray KF, Rosenthal P et al (2017) The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12\u201317 years old with hepatitis C virus genotype 1 infection. Hepatology 66:371\u2013378","journal-title":"Hepatology"},{"key":"429_CR2","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1111\/jvh.12534","volume":"23","author":"C Bunchorntavakul","year":"2016","unstructured":"Bunchorntavakul C, Reddy KR (2016) Treat chronic hepatitis C virus infection in decompensated cirrhosis\u2014pre- or post-liver\u00a0transplantation? The ironic conundrum in the era of effective and well-tolerated therapy. J\u00a0Viral Hepat 23:408\u2013418","journal-title":"J Viral Hepat"},{"key":"429_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","volume":"65","author":"A Desnoyer","year":"2016","unstructured":"Desnoyer A, Pospai D, L\u00ea MP et al (2016) Pharmacokinetics, safety and efficacy of a\u00a0full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J\u00a0Hepatol 65:40\u201347","journal-title":"J Hepatol"},{"issue":"suppl 1","key":"429_CR4","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1053\/j.gastro.2004.09.014","volume":"127","author":"G Fattovich","year":"2004","unstructured":"Fattovich G, Stroffolini T, Zagni I, Donato F (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127(suppl 1):S35\u2013S50","journal-title":"Gastroenterology"},{"key":"429_CR5","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1056\/NEJMc1505967","volume":"373","author":"H Fontaine","year":"2015","unstructured":"Fontaine H, Lazarus A, Pol S et\u00a0al (2015) Bradyarrhythmias associated with sofosbuvir treatment. N\u00a0Engl J Med 373:1886\u20131888","journal-title":"N Engl J Med"},{"key":"429_CR6","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3851\/IMP3066","volume":"21","author":"EJ Gane","year":"2016","unstructured":"Gane EJ, Hyland RH, An D et al (2016) Ledipasvir\u00a0and\u00a0sofosbuvir\u00a0for\u00a0HCV-infection in patients coinfected with\u00a0HBV. Antivir Ther (Lond) 21:605\u2013609","journal-title":"Antivir. Ther. (Lond.)"},{"key":"429_CR7","first-page":"121A","volume":"66","author":"C Hedskog","year":"2017","unstructured":"Hedskog C, Bhardwaj NC et al (2017) Identification of novel HCV genotype and subtypes in patients treated with sofosbuvir-based regimens. Hepatology 66:121A","journal-title":"Hepatology"},{"key":"429_CR8","doi-asserted-by":"publisher","first-page":"218A","DOI":"10.1002\/hep.27455","volume":"60","author":"AM Hill","year":"2014","unstructured":"Hill AM, Saleem J, Heath KA, Simmons B (2014) Effects of sustained virological response (SVR) on the risk of liver transplant, hepatocellular carcinoma, death and re-infection: meta-analysis of 129 studies in 23,309 patients with Hepatitis C infection. Hepatology 60:218A\u2013219A","journal-title":"Hepatology"},{"key":"429_CR9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/infdis\/jis385","volume":"206","author":"MH Lee","year":"2012","unstructured":"Lee MH, Yang HI, Lu SN et al (2012) Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a\u00a0community-based long-term prospective study. J\u00a0Infect Dis 206:469\u2013477","journal-title":"J Infect Dis"},{"key":"429_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(18)30002-5","author":"MM M\u00fccke","year":"2018","unstructured":"M\u00fccke MM, Backus LI, M\u00fccke VT et al (2018) Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a\u00a0systematic review and meta-analysis. Lancet Gastroenterol Hepatol. \n                    https:\/\/doi.org\/10.1016\/S2468-1253(18)30002-5","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"429_CR11","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","volume":"349","author":"T Poynard","year":"1997","unstructured":"Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349:825\u2013832","journal-title":"Lancet"},{"key":"429_CR12","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/cid\/ciw676","volume":"64","author":"C Sarrazin","year":"2017","unstructured":"Sarrazin C, Isakov V, Svarovskaia ES et al (2017) Late relapse versus hepatitis C virus reinfection in patients with sustained virologic response After sofosbuvir-based therapies. Clin Infect Dis 64:44\u201352","journal-title":"Clin Infect Dis"},{"key":"429_CR13","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","volume":"138","author":"C Sarrazin","year":"2010","unstructured":"Sarrazin C, Zeuzem S (2010) Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 138:447\u2013462","journal-title":"Gastroenterology"},{"key":"429_CR14","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1111\/liv.13102","volume":"36","author":"V Saxena","year":"2016","unstructured":"Saxena V, Koraishy FM, Sise ME et al (2016) Safety and efficacy of\u00a0sofosbuvir-containing regimens in hepatitis C\u2011infected patients with impaired renal\u00a0function. Liver Int 36:807\u2013816","journal-title":"Liver Int"},{"key":"429_CR15","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1093\/cid\/civ948","volume":"62","author":"B Simmons","year":"2016","unstructured":"Simmons B, Saleem J, Hill A et al (2016) Risk of late relapse or reinfection with hepatitis C virus after achieving a\u00a0sustained virological response: A systematic review and meta-analysis. Clin Infect Dis 62:683\u2013694","journal-title":"Clin Infect Dis"},{"key":"429_CR16","volume-title":"HEP Drug Interaction","author":"University of Liverpool","year":"2018","unstructured":"University of Liverpool (2018) HEP Drug Interaction. \n                    http:\/\/www.hep-druginteractions.org\n                    \n                  . Zugegriffen: 17. Febr. 2018"},{"key":"429_CR17","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","volume":"67","author":"R Waziry","year":"2017","unstructured":"Waziry R, Hajarizadeh B, Grebely J et al (2017) Hepatocellular carcinoma risk following direct-acting antiviral\u00a0HCV\u00a0therapy: a systematic review, meta-analyses, and meta-regression. J\u00a0Hepatol 67:1204\u20131212","journal-title":"J Hepatol"},{"key":"429_CR18","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0140-6736(14)62401-6","volume":"385","author":"DP Webster","year":"2015","unstructured":"Webster DP, Klenerman P, Dusheiko GM (2015) Hepatitis C. Lancet 385:1124\u20131135","journal-title":"Lancet"},{"key":"429_CR19","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jhep.2015.11.034","volume":"64","author":"M Welker","year":"2016","unstructured":"Welker M, Luhne S, Lange CM et\u00a0al (2016) Lactic acidosis in patients with hepatitis C virus cirrhosis and combined ribavirin\/sofosbuvir treatment. J\u00a0Hepatol 64:790\u2013799","journal-title":"J Hepatol"},{"key":"429_CR20","volume-title":"Combating hepatitis B and C to reach elimination by 2030","author":"WHO","year":"2016","unstructured":"WHO (2016) Combating hepatitis B and C to reach elimination by 2030. \n                    http:\/\/apps.who.int\/iris\/bitstream\/10665\/206453\/1\/WHO_HIV_2016.04_eng.pdf?ua=1\n                    \n                  . Zugegriffen: 17. Febr. 2018"},{"key":"429_CR21","first-page":"597","volume":"114","author":"MA W\u00f6rns","year":"2017","unstructured":"W\u00f6rns MA, Galle PR, Zeuzem S et\u00a0al (2017) Drug treatment for chronic hepatitis C infection and cancer risk. Dtsch Arztebl Int 114:597\u2013602","journal-title":"Dtsch Arztebl Int"},{"key":"429_CR22","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1038\/nrgastro.2014.164","volume":"11","author":"S Zeuzem","year":"2014","unstructured":"Zeuzem S (2014) Decade in review-HCV: hepatitis C therapy\u2014a\u00a0fast and competitive race. Nat Rev Gastroenterol Hepatol 11:644\u2013645","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"429_CR23","first-page":"11","volume":"114","author":"S Zeuzem","year":"2017","unstructured":"Zeuzem S (2017) Treatment options in hepatitis C\u2014the current state of the art. Dtsch Arztebl Int 114:11\u201321","journal-title":"Dtsch Arztebl Int"},{"key":"429_CR24","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1055\/s-0042-107360","volume":"54","author":"T Zimmermann","year":"2016","unstructured":"Zimmermann T, Beckebaum S, Berg C et\u00a0al (2016) Empfehlungen zur antiviralen Therapie der chronischen Hepatitis C bei Patienten auf der Warteliste und nach Transplantation. Z\u00a0Gastroenterol 54:665\u2013684","journal-title":"Z Gastroenterol"},{"key":"429_CR25","unstructured":"Zusammenfassung der Merkmale des Arzneimittels Epclusa (Fachinformation): \n                    http:\/\/ec.europa.eu\/health\/documents\/community-register\/2016\/20160706135323\/anx_135323_de.pdf\n                    \n                  . Zugegriffen: 17.02.2018"},{"key":"429_CR26","unstructured":"Zusammenfassung der Merkmale des Arzneimittels Harvoni (Fachinformation): \n                    http:\/\/ec.europa.eu\/health\/documents\/community-register\/2014\/20141117130011\/anx_130011_de.pdf\n                    \n                  . Zugegriffen: 17.02.2018"},{"key":"429_CR27","unstructured":"Zusammenfassung der Merkmale des Arzneimittels Maviret (Fachinformation): \n                    https:\/\/ec.europa.eu\/health\/documents\/community-register\/2017\/20170726138539\/anx_138539_de.pdf\n                    \n                  . Zugegriffen: 17.02.2018"},{"key":"429_CR28","unstructured":"Zusammenfassung der Merkmale des Arzneimittels Sovaldi (Fachinformation): \n                    https:\/\/ec.europa.eu\/health\/documents\/community-register\/2014\/20140116127595\/anx_127595_en.pdf\n                    \n                  . Zugegriffen: 17.02.2018"},{"key":"429_CR29","unstructured":"Zusammenfassung der Merkmale des Arzneimittels Vosevi (Fachinformation): \n                    https:\/\/ec.europa.eu\/health\/documents\/community-register\/2017\/20170726138516\/anx_138516_de.pdf\n                    \n                  . Zugegriffen: 17.02.2018"},{"key":"429_CR30","unstructured":"Zusammenfassung der Merkmale des Arzneimittels Zepatier (Fachinformation): \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004126\/WC500211235.pdf\n                    \n                  . Zugegriffen: 17.02.2018"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-018-0429-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0429-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-018-0429-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T23:27:40Z","timestamp":1556148460000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-018-0429-y"}},"subtitle":["Standardtherapie und verbliebene Herausforderungen"],"short-title":[],"issued":{"date-parts":[[2018,4,25]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["429"],"URL":"https:\/\/doi.org\/10.1007\/s00108-018-0429-y","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,25]]},"assertion":[{"value":"25 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"S.\u00a0Zeuzem hat an zahlreichen klinischen Studien, die die Sicherheit, Vertr\u00e4glichkeit und Wirksamkeit antiviraler HCV-Medikamente untersuchten, teilgenommen bzw. diese geleitet. Er ber\u00e4t die Firmen AbbVie, Gilead und Merck\/MSD Sharp & Dohme wissenschaftlich auf dem Gebiet der Hepatitis-C-Therapie und erh\u00e4lt Honorare von diesen Firmen f\u00fcr Vortr\u00e4ge bei Fortbildungsveranstaltungen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine vom Autor durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}]}}